Testing adebrelimab, dalpiciclib, and hormone therapy for advanced breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of a new immunotherapy drug (adebrelimab) with a targeted pill (dalpiciclib) and standard hormone therapy for women with advanced hormone receptor positive, HER2 negative breast cancer. It may help patients who have not yet had certain prior treatments, aiming to slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 75, and you are either premenopausal, perimenopausal, or postmenopausal.
- Your breast cancer is hormone receptor positive (ER and/or PR positive) and HER2 negative, and it is advanced (can't be surgically removed) or has spread to other parts of the body.
- You have not received any prior treatment with a CDK4/6 inhibitor (like palbociclib) or an immunotherapy drug (like a checkpoint inhibitor).
- You have not had more than one line of chemotherapy for advanced disease, and you either have not had any systemic therapy for advanced disease or had only one prior line of endocrine therapy.
- You do not have uncontrolled brain metastases, serious heart problems, or an active autoimmune disease or weakened immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding a targeted drug (CDK4/6 inhibitor) to hormone therapy works better than hormone therapy alone for women with a certain type of breast cancer (HR+/HER2-). The study measures the activity of tumor cells (Ki-67) to help decide treatment.
This trial tests whether adding the drug dalpiciclib to standard hormone therapy improves outcomes for people with a certain type of early breast cancer (hormone receptor-positive, HER2-negative). It may help lower the risk of the cancer coming back.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy before surgery for people with high-risk, hormone receptor-positive, HER2-negative breast cancer. The goal is to see if this approach can shrink tumors more effectively than chemotherapy alone.
This trial tests a combination of three targeted drugs for a type of advanced breast cancer that is both ER-positive and HER2-positive. The goal is to see if adding these two new drugs to standard hormone therapy can help shrink or control the cancer.
This trial tests a combination of radiation to the brain, a hormone therapy, and a targeted drug called dalpiciclib for people with advanced breast cancer that has spread to the brain. The goal is to see if this combination can help control the cancer in the brain and elsewhere.
This trial studies whether dalpiciclib can slow down or control advanced hormone receptor–positive breast cancer and assess how safe it is. It’s for people whose cancer has come back in a limited way or spread and can’t be fully cured with surgery or radiation.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.